GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (FRA:C5G) » Definitions » Capex-to-Operating-Income

Orexo AB (FRA:C5G) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Orexo AB Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Orexo AB's Capital Expenditure for the three months ended in Mar. 2025 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was €-0.48 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Orexo AB Capex-to-Operating-Income Historical Data

The historical data trend for Orexo AB's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB Capex-to-Operating-Income Chart

Orexo AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Orexo AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Orexo AB's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Orexo AB's Capex-to-Operating-Income falls into.


;
;

Orexo AB Capex-to-Operating-Income Calculation

Orexo AB's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.409) / -12.736
=N/A

Orexo AB's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.475
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orexo AB  (FRA:C5G) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Orexo AB Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Orexo AB's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Orexo AB Business Description

Industry
Traded in Other Exchanges
Address
Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB Headlines

No Headlines